{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T21:58:34Z","timestamp":1773871114505,"version":"3.50.1"},"reference-count":113,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T00:00:00Z","timestamp":1645747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T00:00:00Z","timestamp":1645747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s40263-021-00888-9","type":"journal-article","created":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T17:05:07Z","timestamp":1645808707000},"page":"261-282","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["COMT Inhibitors in the Management of Parkinson\u2019s Disease"],"prefix":"10.1007","volume":"36","author":[{"given":"Margherita","family":"Fabbri","sequence":"first","affiliation":[]},{"given":"Joaquim J.","family":"Ferreira","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1410-6397","authenticated-orcid":false,"given":"Olivier","family":"Rascol","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2022,2,25]]},"reference":[{"issue":"1","key":"888_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1001\/jamaneurol.2017.3299","volume":"75","author":"ER Dorsey","year":"2018","unstructured":"Dorsey ER, Bloem BR. The Parkinson pandemic: a call to action. JAMA Neurol. 2018;75(1):9\u201310.","journal-title":"JAMA Neurol"},{"issue":"1","key":"888_CR2","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/mds.26082","volume":"30","author":"PA LeWitt","year":"2015","unstructured":"LeWitt PA. Levodopa therapy for Parkinson\u2019s disease: pharmacokinetics and pharmacodynamics. Move Disord. 2015;30(1):64\u201372.","journal-title":"Move Disord."},{"issue":"6","key":"888_CR3","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1002\/mds.27386","volume":"33","author":"K Ray Chaudhuri","year":"2018","unstructured":"Ray Chaudhuri K, Poewe W, Brooks D. Motor and nonmotor complications of levodopa: phenomenology, risk factors, and imaging features. Move Disord. 2018;33(6):909\u201319.","journal-title":"Move Disord."},{"issue":"11","key":"888_CR4","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/j.parkreldis.2014.09.013","volume":"20","author":"A Rizos","year":"2014","unstructured":"Rizos A, Martinez-Martin P, Odin P, Antonini A, Kessel B, Kozul TK, et al. Characterizing motor and non-motor aspects of early-morning off periods in Parkinson\u2019s disease: an international multicenter study. Parkinsonism Relat Disord. 2014;20(11):1231\u20135.","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"888_CR5","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s40263-015-0306-3","volume":"30","author":"SL Greig","year":"2016","unstructured":"Greig SL, McKeage K. Carbidopa\/levodopa ER capsules (Rytary\u00ae, Numient\u2122): a review in Parkinson\u2019s disease. CNS Drugs. 2016;30(1):79\u201390.","journal-title":"CNS Drugs"},{"issue":"10","key":"888_CR6","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1002\/mds.28726","volume":"36","author":"CW Olanow","year":"2021","unstructured":"Olanow CW, Poewe W, Rascol O, Stocchi F. On-demand therapy for OFF episodes in Parkinson\u2019s disease. Move Disord. 2021;36(10):2243\u201353.","journal-title":"Move Disord."},{"issue":"s1","key":"888_CR7","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.3233\/JPD-202104","volume":"10","author":"JM Dijk","year":"2020","unstructured":"Dijk JM, Espay AJ, Katzenschlager R, de Bie RMA. The choice between advanced therapies for Parkinson\u2019s disease patients: why, what, and when? J Parkinsons Dis. 2020;10(s1):S65-73.","journal-title":"J Parkinsons Dis"},{"issue":"12","key":"888_CR8","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s40266-018-0599-2","volume":"35","author":"M Fabbri","year":"2018","unstructured":"Fabbri M, Rosa MM, Ferreira JJ. Adjunctive therapies in Parkinson\u2019s disease: how to choose the best treatment strategy approach. Drugs Aging. 2018;35(12):1041\u201354.","journal-title":"Drugs Aging"},{"issue":"8","key":"888_CR9","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1002\/mds.27372","volume":"33","author":"SH Fox","year":"2018","unstructured":"Fox SH, Katzenschlager R, Lim SY, Barton B, de Bie RMA, Seppi K, et al. International Parkinson and Movement Disorder Society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson\u2019s disease. Move Disord. 2018;33(8):1248\u201366.","journal-title":"Move Disord."},{"issue":"6","key":"888_CR10","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/S1474-4422(05)70098-3","volume":"4","author":"A Schrag","year":"2005","unstructured":"Schrag A. Entacapone in the treatment of Parkinson\u2019s disease. Lancet Neurol. 2005;4(6):366\u201370.","journal-title":"Lancet Neurol"},{"issue":"3\u20134","key":"888_CR11","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1159\/000479555","volume":"78","author":"J Li","year":"2017","unstructured":"Li J, Lou Z, Liu X, Sun Y, Chen J. Efficacy and safety of adjuvant treatment with entacapone in advanced Parkinson\u2019s disease with motor fluctuation: a systematic meta-analysis. Eur Neurol. 2017;78(3\u20134):143\u201353.","journal-title":"Eur Neurol"},{"issue":"10","key":"888_CR12","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1002\/mds.27475","volume":"33","author":"M Fabbri","year":"2018","unstructured":"Fabbri M, Ferreira JJ, Lees A, Stocchi F, Poewe W, Tolosa E, et al. Opicapone for the treatment of Parkinson\u2019s disease: a review of a new licensed medicine. Move Disord. 2018;33(10):1528\u201339.","journal-title":"Move Disord."},{"issue":"6","key":"888_CR13","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s00228-020-03081-x","volume":"77","author":"CA Artusi","year":"2021","unstructured":"Artusi CA, Sarro L, Imbalzano G, Fabbri M, Lopiano L. Safety and efficacy of tolcapone in Parkinson\u2019s disease: systematic review. Eur J Clin Pharmacol. 2021;77(6):817\u201329.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1 Suppl. 1","key":"888_CR14","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1212\/WNL.62.1_suppl_1.S31","volume":"62","author":"W Poewe","year":"2004","unstructured":"Poewe W. The role of COMT inhibition in the treatment of Parkinson\u2019s disease. Neurology. 2004;62(1 Suppl. 1):S31\u20138.","journal-title":"Neurology"},{"issue":"11 Suppl. 3","key":"888_CR15","doi-asserted-by":"publisher","first-page":"P25","DOI":"10.1007\/PL00007743","volume":"245","author":"HM Ruottinen","year":"1998","unstructured":"Ruottinen HM, Rinne UK. COMT inhibition in the treatment of Parkinson\u2019s disease. J Neurol. 1998;245(11 Suppl. 3):P25-34.","journal-title":"J Neurol"},{"issue":"1\u20132","key":"888_CR16","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s002280050068","volume":"50","author":"J Dingemanse","year":"1996","unstructured":"Dingemanse J, Jorga K, Z\u00fcrcher G, Fotteler B, Sedek G, Nielsen T, et al. Multiple-dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects. Eur J Clin Pharmacol. 1996;50(1\u20132):47\u201355.","journal-title":"Eur J Clin Pharmacol"},{"issue":"8","key":"888_CR17","doi-asserted-by":"publisher","first-page":"3396","DOI":"10.1021\/jm1001524","volume":"53","author":"LE Kiss","year":"2010","unstructured":"Kiss LE, Ferreira HS, Torrao L, Bonifacio MJ, Palma PN, Soares-da-Silva P, et al. Discovery of a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase. J Med Chem. 2010;53(8):3396\u2013411.","journal-title":"J Med Chem"},{"key":"888_CR18","doi-asserted-by":"publisher","first-page":"S125","DOI":"10.1016\/S1353-8020(11)70565-X","volume":"18","author":"N Palma","year":"2012","unstructured":"Palma N, Bonifacio MJ, Loureiro AI, Soares-Da-Silva P. Computation of binding affinity of catechol-O-methyltransferase-opicapone complexes. Parkinsonism Relat Disord. 2012;18:S125.","journal-title":"Parkinsonism Relat Disord"},{"issue":"7","key":"888_CR19","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1111\/bph.13020","volume":"172","author":"MJ Bonifacio","year":"2015","unstructured":"Bonifacio MJ, Torrao L, Loureiro AI, Palma PN, Wright LC, Soares-da-Silva P. Pharmacological profile of opicapone, a third-generation nitrocatechol catechol-O-methyl transferase inhibitor, in the rat. Br J Pharmacol. 2015;172(7):1739\u201352.","journal-title":"Br J Pharmacol"},{"issue":"1\u20132","key":"888_CR20","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ijpharm.2016.01.074","volume":"501","author":"J Bicker","year":"2016","unstructured":"Bicker J, Alves G, Fortuna A, Soares-da-Silva P, Falcao A. A new PAMPA model using an in-house brain lipid extract for screening the blood-brain barrier permeability of drug candidates. Int J Pharm. 2016;501(1\u20132):102\u201311.","journal-title":"Int J Pharm"},{"key":"888_CR21","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2147\/CIA.S3787","volume":"4","author":"DD Truong","year":"2009","unstructured":"Truong DD. Tolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson\u2019s disease. Clin Interv Aging. 2009;4:109\u201313.","journal-title":"Clin Interv Aging"},{"issue":"3","key":"888_CR22","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/j.1365-2125.1995.tb05781.x","volume":"40","author":"J Dingemanse","year":"1995","unstructured":"Dingemanse J, Jorga K, Z\u00fcrcher G, Schmitt M, Sedek G, Da Prada M, et al. Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa. Br J Clin Pharmacol. 1995;40(3):253\u201362.","journal-title":"Br J Clin Pharmacol"},{"key":"888_CR23","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1097\/00002826-199417003-00006","volume":"17","author":"MBJ Prada","year":"1994","unstructured":"Prada MBJ, Napolitano A. Improved therapy of Parkinson\u2019s disease with tolcapone, a central and peripheral COMT inhibitor with an S-adenosyl-L-methionine-sparing effect. Clin Neuropharmacol. 1994;17:S26\u201337.","journal-title":"Clin Neuropharmacol"},{"issue":"6","key":"888_CR24","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1097\/00002826-199712000-00005","volume":"20","author":"G S\u00eadek","year":"1997","unstructured":"S\u00eadek G, Jorga K, Schmitt M, Burns RS, Leese P. Effect of tolcapone on plasma levodopa concentrations after coadministration with levodopa\/carbidopa to healthy volunteers. Clin Neuropharmacol. 1997;20(6):531\u201341.","journal-title":"Clin Neuropharmacol"},{"issue":"2","key":"888_CR25","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/BF00199880","volume":"46","author":"T Ker\u00e4nen","year":"1994","unstructured":"Ker\u00e4nen T, Gordin A, Karlsson M, Korpela K, Pentik\u00e4inen PJ, Rita H, et al. Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone. Eur J Clin Pharmacol. 1994;46(2):151\u20137.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"888_CR26","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1097\/00002826-199619040-00001","volume":"19","author":"HM Ruottinen","year":"1996","unstructured":"Ruottinen HM, Rinne UK. A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson\u2019s disease. Clin Neuropharmacol. 1996;19(4):283\u201396.","journal-title":"Clin Neuropharmacol"},{"issue":"1","key":"888_CR27","first-page":"81","volume":"21","author":"T Wikberg","year":"1993","unstructured":"Wikberg T, Vuorela A, Ottoila P, Taskinen J. Identification of major metabolites of the catechol-O-methyltransferase inhibitor entacapone in rats and humans. Drug Metab Dispos. 1993;21(1):81\u201392.","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"888_CR28","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/mds.870120404","volume":"12","author":"J Lyytinen","year":"1997","unstructured":"Lyytinen J, Kaakkola S, Ahtila S, Tuomainen P, Ter\u00e4v\u00e4inen H. Simultaneous MAO-B and COMT inhibition in l-dopa-treated patients with Parkinson\u2019s disease. Move Disord. 1997;12(4):497\u2013505.","journal-title":"Move Disord."},{"issue":"5","key":"888_CR29","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1212\/WNL.44.5.913","volume":"44","author":"JG Nutt","year":"1994","unstructured":"Nutt JG, Woodward WR, Beckner RM, Stone CK, Berggren K, Carter JH, et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology. 1994;44(5):913\u20139.","journal-title":"Neurology"},{"issue":"1","key":"888_CR30","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1136\/jnnp.60.1.36","volume":"60","author":"HM Ruottinen","year":"1996","unstructured":"Ruottinen HM, Rinne UK. Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations. J Neurol Neurosurg Psychiatry. 1996;60(1):36\u201340.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"888_CR31","unstructured":"Loureiro A, Fernandes-Lopes C, Wright L, et al. Sulfation of opicapone, a nitrocatechol-type COMT inhibitor, by human recombinant SULTs and human S9 fraction. Abstract, XX World Congress on Parkinson\u2019s Disease and Related Disorders 2013, Switzerland."},{"issue":"2","key":"888_CR32","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s40262-012-0024-7","volume":"52","author":"L Almeida","year":"2013","unstructured":"Almeida L, Rocha JF, Falcao A, Palma PN, Loureiro AI, Pinto R, et al. Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel catechol-O-methyltransferase inhibitor, in healthy subjects: prediction of slow enzyme-inhibitor complex dissociation of a short-living and very long-acting inhibitor. Clin Pharmacokinet. 2013;52(2):139\u201351.","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl. 1","key":"888_CR33","first-page":"123","volume":"24","author":"AFA Santos","year":"2017","unstructured":"Santos AFA, Rocha J, Soares-Da-Silva P. Influence of food on opicapone pharmacokinetics and pharmacodynamics. Eur J Neurol. 2017;24(Suppl. 1):123\u2013444.","journal-title":"Eur J Neurol"},{"issue":"9","key":"888_CR34","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s00228-014-1701-2","volume":"70","author":"JF Rocha","year":"2014","unstructured":"Rocha JF, Falcao A, Santos A, Pinto R, Lopes N, Nunes T, et al. Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations. Eur J Clin Pharmacol. 2014;70(9):1059\u201371.","journal-title":"Eur J Clin Pharmacol"},{"key":"888_CR35","first-page":"S119","volume":"261","author":"JF Rocha","year":"2014","unstructured":"Rocha JF, Falcao A, Lopes N, Pinto R, Santos A, Nunes T, et al. Opicapone effect on levodopa pharmacokinetics in comparison with placebo and entacapone when administered with immediate release 100\/25 mg levodopa\/carbidopa in healthy subjects. J Neurol. 2014;261:S119.","journal-title":"J Neurol"},{"key":"888_CR36","unstructured":"Falc\u00e3o ASA, Ferreira JJ, Rocha J, Soares-Da-Silva P. Opicapone\u2019s bedtime regimen and the decision-making process. Eur J Neurol. 2017;24."},{"issue":"1","key":"888_CR37","first-page":"32","volume":"10","author":"G Z\u00fcrcher","year":"1996","unstructured":"Z\u00fcrcher G, Da Prada M, Dingemanse J. Assessment of catechol-O-methyltransferase activity and its inhibition in erythrocytes of animals and humans. BMC. 1996;10(1):32\u20136.","journal-title":"BMC"},{"issue":"5","key":"888_CR38","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/0009-9236(95)90035-7","volume":"57","author":"J Dingemanse","year":"1995","unstructured":"Dingemanse J, Jorga KM, Schmitt M, Gieschke R, Fotteler B, Z\u00fcrcher G, et al. Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans. Clin Pharmacol Ther. 1995;57(5):508\u201317.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"888_CR39","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/S0009-9236(97)90033-3","volume":"62","author":"KM Jorga","year":"1997","unstructured":"Jorga KM, Sedek G, Fotteler B, Z\u00fcrcher G, Nielsen T, Aitken JW. Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly. Clin Pharmacol Ther. 1997;62(3):300\u201310.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"888_CR40","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1097\/00002826-199619030-00004","volume":"19","author":"HM Ruottinen","year":"1996","unstructured":"Ruottinen HM, Rinne UK. Effect of one month\u2019s treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients. Clin Neuropharmacol. 1996;19(3):222\u201333.","journal-title":"Clin Neuropharmacol"},{"issue":"5","key":"888_CR41","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1111\/bcp.12081","volume":"76","author":"JF Rocha","year":"2013","unstructured":"Rocha JF, Almeida L, Falcao A, Palma PN, Loureiro AI, Pinto R, et al. Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects. Br J Clin Pharmacol. 2013;76(5):763\u201375.","journal-title":"Br J Clin Pharmacol"},{"key":"888_CR42","doi-asserted-by":"crossref","unstructured":"Ferreira JJ, Rocha JF, Falcao A, Santos A, Pinto R, Nunes T, et al. Effects of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson's disease. Eur J Neurol. 2015;22(5):815\u201325e56.","DOI":"10.1111\/ene.12666"},{"issue":"2","key":"888_CR43","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/S1474-4422(15)00336-1","volume":"15","author":"JJ Ferreira","year":"2016","unstructured":"Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P. Opicapone as an adjunct to levodopa in patients with Parkinson\u2019s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol. 2016;15(2):154\u201365.","journal-title":"Lancet Neurol"},{"issue":"5","key":"888_CR44","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/00002826-200109000-00007","volume":"24","author":"SA Factor","year":"2001","unstructured":"Factor SA, Molho ES, Feustel PJ, Brown DL, Evans SM. Long-term comparative experience with tolcapone and entacapone in advanced Parkinson\u2019s disease. Clin Neuropharmacol. 2001;24(5):295\u20139.","journal-title":"Clin Neuropharmacol"},{"issue":"5","key":"888_CR45","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1002\/mds.1175","volume":"16","author":"W Koller","year":"2001","unstructured":"Koller W, Lees A, Doder M, Hely M. Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson\u2019s disease patients with motor fluctuations. Move Disord. 2001;16(5):858\u201366.","journal-title":"Move Disord."},{"key":"888_CR46","doi-asserted-by":"crossref","unstructured":"Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated parkinsonian patients. Tolcapone Study Group. Move Disord. 1999;14(1):38\u201344.","DOI":"10.1002\/1531-8257(199901)14:1<38::AID-MDS1008>3.0.CO;2-I"},{"key":"888_CR47","doi-asserted-by":"crossref","unstructured":"Stowe R, Ives N, Clarke CE, Deane K, Wheatley K, Gray R, et al. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson's disease patients with motor complications. Cochrane Database Syst Rev. 2010;7:CD007166.","DOI":"10.1002\/14651858.CD007166.pub2"},{"issue":"4","key":"888_CR48","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1034\/j.1600-0404.2002.1o174.x","volume":"105","author":"WH Poewe","year":"2002","unstructured":"Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M. Efficacy and safety of entacapone in Parkinson\u2019s disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand. 2002;105(4):245\u201355.","journal-title":"Acta Neurol Scand"},{"issue":"5","key":"888_CR49","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1136\/jnnp.68.5.589","volume":"68","author":"P Piccini","year":"2000","unstructured":"Piccini P, Brooks DJ, Korpela K, Pavese N, Karlsson M, Gordin A. The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 2000;68(5):589\u201394.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"888_CR50","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1001\/jamaneurol.2016.4703","volume":"74","author":"AJ Lees","year":"2017","unstructured":"Lees AJ, Ferreira J, Rascol O, Poewe W, Rocha JF, McCrory M, et al. Opicapone as adjunct to levodopa therapy in patients with Parkinson disease and motor fluctuations: a randomized clinical trial. JAMA Neurol. 2017;74(2):197\u2013206.","journal-title":"JAMA Neurol"},{"issue":"2","key":"888_CR51","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1002\/mds.28322","volume":"36","author":"A Takeda","year":"2021","unstructured":"Takeda A, Takahashi R, Tsuboi Y, Nomoto M, Maeda T, Nishimura A, et al. Randomized, controlled study of opicapone in Japanese Parkinson\u2019s patients with motor fluctuations. Move Disord. 2021;36(2):415\u201323.","journal-title":"Move Disord."},{"issue":"7","key":"888_CR52","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1111\/ene.13914","volume":"26","author":"JJ Ferreira","year":"2019","unstructured":"Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P. Long-term efficacy of opicapone in fluctuating Parkinson\u2019s disease patients: a pooled analysis of data from two phase 3 clinical trials and their open-label extensions. Eur J Neurol. 2019;26(7):953\u201360.","journal-title":"Eur J Neurol"},{"issue":"21","key":"888_CR53","doi-asserted-by":"publisher","first-page":"e1849","DOI":"10.1212\/WNL.0000000000005557","volume":"90","author":"JJ Ferreira","year":"2018","unstructured":"Ferreira JJ, Lees AJ, Poewe W, Rascol O, Rocha JF, Keller B, et al. Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease. Neurology. 2018;90(21):e1849\u201357.","journal-title":"Neurology"},{"key":"888_CR54","unstructured":"Takeda ATR, Tsuboi Y, Nomoto M, Maeda T, Nishimura A, Hattori N. An open-label, 1-year extension clinical study in Japan of opicapone treatment for Parkinson\u2019s disease: comfort-PD study part 2. Move Disord. 2019;34(S2)."},{"issue":"1","key":"888_CR55","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/ana.22060","volume":"68","author":"F Stocchi","year":"2010","unstructured":"Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, et al. Initiating levodopa\/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol. 2010;68(1):18\u201327.","journal-title":"Ann Neurol"},{"issue":"8","key":"888_CR56","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1002\/mds.25364","volume":"28","author":"C Warren Olanow","year":"2013","unstructured":"Warren Olanow C, Kieburtz K, Rascol O, Poewe W, Schapira AH, Emre M, et al. Factors predictive of the development of levodopa-induced dyskinesia and wearing-off in Parkinson\u2019s disease. Move Disord. 2013;28(8):1064\u201371.","journal-title":"Move Disord."},{"issue":"4","key":"888_CR57","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/mds.22343","volume":"24","author":"RA Hauser","year":"2009","unstructured":"Hauser RA, Panisset M, Abbruzzese G, Mancione L, Dronamraju N, Kakarieka A. Double-blind trial of levodopa\/carbidopa\/entacapone versus levodopa\/carbidopa in early Parkinson\u2019s disease. Move Disord. 2009;24(4):541\u201350.","journal-title":"Move Disord."},{"issue":"7","key":"888_CR58","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1212\/WNL.0b013e318281cc99","volume":"80","author":"DC Velseboer","year":"2013","unstructured":"Velseboer DC, Broeders M, Post B, van Geloven N, Speelman JD, Schmand B, et al. Prognostic factors of motor impairment, disability, and quality of life in newly diagnosed PD. Neurology. 2013;80(7):627\u201333.","journal-title":"Neurology"},{"issue":"7","key":"888_CR59","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1002\/mds.21429","volume":"22","author":"A Schrag","year":"2007","unstructured":"Schrag A, Dodel R, Spottke A, Bornschein B, Siebert U, Quinn NP. Rate of clinical progression in Parkinson\u2019s disease: a prospective study. Move Disord. 2007;22(7):938\u201345.","journal-title":"Move Disord."},{"key":"888_CR60","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.parkreldis.2019.02.043","volume":"64","author":"M Fabbri","year":"2019","unstructured":"Fabbri M, Coelho M, Abreu D, Guedes LC, Rosa MM, Godinho C, et al. Dysphagia predicts poor outcome in late-stage Parkinson\u2019s disease. Parkinsonism Relat Disord. 2019;64:73\u201381.","journal-title":"Parkinsonism Relat Disord"},{"issue":"8","key":"888_CR61","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1002\/mds.20914","volume":"21","author":"A Schrag","year":"2006","unstructured":"Schrag A, Sampaio C, Counsell N, Poewe W. Minimal clinically important change on the unified Parkinson\u2019s disease rating scale. Move Disord. 2006;21(8):1200\u20137.","journal-title":"Move Disord."},{"issue":"5 Suppl. 5","key":"888_CR62","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1212\/WNL.50.5_Suppl_5.S39","volume":"50","author":"CH Waters","year":"1998","unstructured":"Waters CH, Kurth M, Bailey P, Shulman LM, LeWitt P, Dorflinger E, et al. Tolcapone in stable Parkinson\u2019s disease: efficacy and safety of long-term treatment. Tolcapone Stable Study Group. Neurology. 1998;50(5 Suppl. 5):S39-45.","journal-title":"Neurology"},{"issue":"1","key":"888_CR63","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1159\/000050749","volume":"46","author":"M Onofrj","year":"2001","unstructured":"Onofrj M, Thomas A, Iacono D, Di Iorio A, Bonanni L. Switch-over from tolcapone to entacapone in severe Parkinson\u2019s disease patients. Eur Neurol. 2001;46(1):11\u20136.","journal-title":"Eur Neurol"},{"issue":"1","key":"888_CR64","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/mds.21131","volume":"22","author":"Entacapone to tolcapone switch","year":"2007","unstructured":"Entacapone to tolcapone switch. Multicenter double-blind, randomized, active-controlled trial in advanced Parkinson\u2019s disease. Move Disord. 2007;22(1):14\u20139.","journal-title":"Move Disord."},{"issue":"2","key":"888_CR65","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1046\/j.1468-1331.2003.00559.x","volume":"10","author":"JP Larsen","year":"2003","unstructured":"Larsen JP, Worm-Petersen J, Sid\u00e9n A, Gordin A, Reinikainen K, Leinonen M. The tolerability and efficacy of entacapone over 3 years in patients with Parkinson\u2019s disease. Eur J Neurol. 2003;10(2):137\u201346.","journal-title":"Eur J Neurol"},{"key":"888_CR66","doi-asserted-by":"crossref","unstructured":"Hauser RRO, Poewe W, Ferreira JJ, Lees A, Klepitskaya G, Liang G, et al. Opicapone as a levodopa sparing agent: pooled analysis of BIPARK-I and II double-blind trials. Move Disord. 2019;34(Suppl. S2):S46.","DOI":"10.1016\/j.jns.2019.10.1209"},{"key":"888_CR67","doi-asserted-by":"crossref","unstructured":"Adler CH, Singer C, O'Brien C, Hauser RA, Lew MF, Marek KL, et al. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III. Arch Neurol. 1998;55(8):1089\u201395.","DOI":"10.1001\/archneur.55.8.1089"},{"issue":"3","key":"888_CR68","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/1531-8257(200005)15:3<497::AID-MDS1012>3.0.CO;2-4","volume":"15","author":"MD Welsh","year":"2000","unstructured":"Welsh MD, Dorflinger E, Chernik D, Waters C. Illness impact and adjustment to Parkinson\u2019s disease: before and after treatment with tolcapone. Move Disord. 2000;15(3):497\u2013502.","journal-title":"Move Disord."},{"issue":"4","key":"888_CR69","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1136\/jnnp.63.4.421","volume":"63","author":"H Baas","year":"1997","unstructured":"Baas H, Beiske AG, Ghika J, Jackson M, Oertel WH, Poewe W, et al. Catechol-O-methyltransferase inhibition with tolcapone reduces the \u201cwearing off\u201d phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry. 1997;63(4):421\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"888_CR70","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/j.1600-0404.2004.00363.x","volume":"111","author":"H Reichmann","year":"2005","unstructured":"Reichmann H, Boas J, Macmahon D, Myllyla V, Hakala A, Reinikainen K. Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations. Acta Neurol Scand. 2005;111(1):21\u20138.","journal-title":"Acta Neurol Scand"},{"issue":"3","key":"888_CR71","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s00702-002-0799-z","volume":"110","author":"G F\u00e9nelon","year":"2003","unstructured":"F\u00e9nelon G, Gim\u00e9nez-Rold\u00e1n S, Montastruc JL, Bermejo F, Durif F, Bourdeix I, et al. Efficacy and tolerability of entacapone in patients with Parkinson\u2019s disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations: a randomized, double-blind, multicentre study. J Neural Transm (Vienna). 2003;110(3):239\u201351.","journal-title":"J Neural Transm (Vienna)"},{"issue":"3","key":"888_CR72","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/j.1468-1331.2006.01635.x","volume":"14","author":"F Grandas","year":"2007","unstructured":"Grandas F, Hernandez B. Long-term effectiveness and quality of life improvement in entacapone-treated Parkinson\u2019s disease patients: the effects of an early therapeutic intervention. Eur J Neurol. 2007;14(3):282\u20139.","journal-title":"Eur J Neurol"},{"issue":"6","key":"888_CR73","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/S0278-5846(03)00156-8","volume":"27","author":"O Gershanik","year":"2003","unstructured":"Gershanik O, Emre M, Bernhard G, Sauer D. Efficacy and safety of levodopa with entacapone in Parkinson\u2019s disease patients suboptimally controlled with levodopa alone, in daily clinical practice: an international, multicentre, open-label study. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(6):963\u201371.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"2","key":"888_CR74","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1159\/000052104","volume":"45","author":"F Durif","year":"2001","unstructured":"Durif F, Devaux I, Pere JJ, Delumeau JC, Bourdeix I. Efficacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson\u2019s disease and end-of-dose deterioration in daily medical practice: an open, multicenter study. Eur Neurol. 2001;45(2):111\u20138.","journal-title":"Eur Neurol"},{"issue":"1","key":"888_CR75","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40035-020-00187-1","volume":"9","author":"H Reichmann","year":"2020","unstructured":"Reichmann H, Lees A, Rocha JF, Magalh\u00e3es D, Soares-da-Silva P. Effectiveness and safety of opicapone in Parkinson\u2019s disease patients with motor fluctuations: the OPTIPARK open-label study. Transl Neurodegener. 2020;9(1):9.","journal-title":"Transl Neurodegener."},{"issue":"7","key":"888_CR76","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/nrn.2017.62","volume":"18","author":"AHV Schapira","year":"2017","unstructured":"Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. Nat Rev Neurosci. 2017;18(7):435\u201350.","journal-title":"Nat Rev Neurosci"},{"issue":"2","key":"888_CR77","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1177\/1756285613512392","volume":"7","author":"T M\u00fcller","year":"2014","unstructured":"M\u00fcller T. Tolcapone addition improves Parkinson\u2019s disease associated nonmotor symptoms. Ther Adv Neurol Disord. 2014;7(2):77\u201382.","journal-title":"Ther Adv Neurol Disord"},{"key":"888_CR78","doi-asserted-by":"crossref","unstructured":"Ebersbach G, Hahn K, Lorrain M, Storch A. Tolcapone improves sleep in patients with advanced Parkinson's disease (PD). Arch Gerontol Geriatr. 2010;51(3):e125\u20138.","DOI":"10.1016\/j.archger.2010.03.008"},{"issue":"8\u20139","key":"888_CR79","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/BF01285556","volume":"104","author":"M Gasparini","year":"1997","unstructured":"Gasparini M, Fabrizio E, Bonifati V, Meco G. Cognitive improvement during tolcapone treatment in Parkinson\u2019s disease. J Neural Transm (Vienna). 1997;104(8\u20139):887\u201394.","journal-title":"J Neural Transm (Vienna)"},{"key":"888_CR80","first-page":"191","volume":"22","author":"C Oliveira","year":"2015","unstructured":"Oliveira C, Lees A, Ferreira J, Lopes N, Costa R, Pinto R, et al. Evaluation of non-motor symptoms in opicapone treated Parkinson\u2019s disease patients: results from a double-blind, randomized, placebo-controlled study and open-label extension. Eur J Neurol. 2015;22:191.","journal-title":"Eur J Neurol"},{"issue":"9","key":"888_CR81","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1212\/WNL.58.9.1381","volume":"58","author":"MA Hern\u00e1n","year":"2002","unstructured":"Hern\u00e1n MA, Checkoway H, O\u2019Brien R, Costa-Mallen P, De Vivo I, Colditz GA, et al. MAOB intron 13 and COMT codon 158 polymorphisms, cigarette smoking, and the risk of PD. Neurology. 2002;58(9):1381\u20137.","journal-title":"Neurology"},{"issue":"1","key":"888_CR82","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/ana.22155","volume":"69","author":"JC Corvol","year":"2011","unstructured":"Corvol JC, Bonnet C, Charbonnier-Beaupel F, Bonnet AM, Fi\u00e9vet MH, Bellanger A, et al. The COMT Val158Met polymorphism affects the response to entacapone in Parkinson\u2019s disease: a randomized crossover clinical trial. Ann Neurol. 2011;69(1):111\u20138.","journal-title":"Ann Neurol"},{"issue":"2","key":"888_CR83","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1474-4422(13)70293-X","volume":"13","author":"CW Olanow","year":"2014","unstructured":"Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson\u2019s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014;13(2):141\u20139.","journal-title":"Lancet Neurol"},{"issue":"6","key":"888_CR84","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1111\/j.1468-1331.2011.03614.x","volume":"19","author":"D Nyholm","year":"2012","unstructured":"Nyholm D, Johansson A, Lennern\u00e4s H, Askmark H. Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial. Eur J Neurol. 2012;19(6):820\u20136.","journal-title":"Eur J Neurol"},{"issue":"1","key":"888_CR85","doi-asserted-by":"publisher","first-page":"18057","DOI":"10.1038\/s41598-020-75052-2","volume":"10","author":"M Senek","year":"2020","unstructured":"Senek M, Nyholm D, Nielsen EI. Population pharmacokinetics of levodopa gel infusion in Parkinson\u2019s disease: effects of entacapone infusion and genetic polymorphism. Sci Rep. 2020;10(1):18057.","journal-title":"Sci Rep"},{"issue":"4","key":"888_CR86","doi-asserted-by":"publisher","first-page":"254","DOI":"10.3390\/jpm11040254","volume":"11","author":"M \u00d6thman","year":"2021","unstructured":"\u00d6thman M, Widman E, Nygren I, Nyholm D. Initial experience of the levodopa-entacapone-carbidopa intestinal gel in clinical practice. J Pers Med. 2021;11(4):254.","journal-title":"J Pers Med."},{"issue":"7","key":"888_CR87","first-page":"854","volume":"7","author":"N Schr\u00f6ter","year":"2020","unstructured":"Schr\u00f6ter N, Ahrendt S, Hager A, Rijntjes M. Addition of tolcapone in intrajejunal levodopa infusion therapy requires a pronounced cost reduction. Move Disord. 2020;7(7):854\u20136.","journal-title":"Move Disord."},{"issue":"4","key":"888_CR88","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.3233\/JPD-202022","volume":"10","author":"V Leta","year":"2020","unstructured":"Leta V, van Wamelen DJ, Sauerbier A, Jones S, Parry M, Rizos A, et al. Opicapone and levodopa-carbidopa intestinal gel infusion: the way forward towards cost savings for healthcare systems? J Parkinsons Dis. 2020;10(4):1535\u20139.","journal-title":"J Parkinsons Dis"},{"key":"888_CR89","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.parkreldis.2021.09.024","volume":"91","author":"N Giladi","year":"2021","unstructured":"Giladi N, Gurevich T, Djaldetti R, Adar L, Case R, Leibman-Barak S, et al. ND0612 (levodopa\/carbidopa for subcutaneous infusion) in patients with Parkinson\u2019s disease and motor response fluctuations: a randomized, placebo-controlled phase 2 study. Parkinsonism Relat Disord. 2021;91:139\u201345.","journal-title":"Parkinsonism Relat Disord"},{"issue":"9132","key":"888_CR90","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/S0140-6736(05)61511-5","volume":"352","author":"F Assal","year":"1998","unstructured":"Assal F, Spahr L, Hadengue A, Rubbia-Brandt L, Burkhard PR. Tolcapone and fulminant hepatitis. Lancet. 1998;352(9132):958.","journal-title":"Lancet"},{"issue":"2","key":"888_CR91","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1001\/archneur.57.2.263","volume":"57","author":"CW Olanow","year":"2000","unstructured":"Olanow CW. Tolcapone and hepatotoxic effects. Tasmar Advisory Panel Arch Neurol. 2000;57(2):263\u20137.","journal-title":"Tasmar Advisory Panel Arch Neurol."},{"issue":"5","key":"888_CR92","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1097\/wnf.0b013e318038d2b6","volume":"30","author":"CW Olanow","year":"2007","unstructured":"Olanow CW, Watkins PB. Tolcapone: an efficacy and safety review (2007). Clin Neuropharmacol. 2007;30(5):287\u201394.","journal-title":"Clin Neuropharmacol"},{"key":"888_CR93","doi-asserted-by":"crossref","unstructured":"Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Parkinson Study Group. Ann Neurol. 1997;42(5):747\u201355.","DOI":"10.1002\/ana.410420511"},{"issue":"5","key":"888_CR94","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1212\/WNL.51.5.1309","volume":"51","author":"UK Rinne","year":"1998","unstructured":"Rinne UK, Larsen JP, Siden A, Worm-Petersen J. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology. 1998;51(5):1309\u201314.","journal-title":"Neurology"},{"key":"888_CR95","doi-asserted-by":"crossref","unstructured":"Brooks DJ, Sagar H, Group UK-IES. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study. J Neurol Neurosurg Psychiatry. 2003;74(8):1071\u20139.","DOI":"10.1136\/jnnp.74.8.1071"},{"key":"888_CR96","doi-asserted-by":"crossref","unstructured":"Myllyla VV, Kultalahti ER, Haapaniemi H, Leinonen M, Group FS. Twelve-month safety of entacapone in patients with Parkinson's disease. Eur J Neurol. 2001;8(1):53\u201360.","DOI":"10.1046\/j.1468-1331.2001.00168.x"},{"issue":"8","key":"888_CR97","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1007\/s10072-020-04303-x","volume":"41","author":"X Liao","year":"2020","unstructured":"Liao X, Wu N, Liu D, Shuai B, Li S, Li K. Levodopa\/carbidopa\/entacapone for the treatment of early Parkinson\u2019s disease: a meta-analysis. Neurol Sci. 2020;41(8):2045\u201354.","journal-title":"Neurol Sci"},{"issue":"Suppl. 1","key":"888_CR98","first-page":"S57","volume":"7","author":"HRK Haapaniemi","year":"2000","unstructured":"Haapaniemi HRK, Leinonen M. Tolerability and safety of entacapone in the treatment of Parkinson\u2019s disease. Parkinsonism Relat Disord. 2000;7(Suppl. 1):S57.","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"888_CR99","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1080\/14740338.2018.1433659","volume":"17","author":"A Castro Caldas","year":"2018","unstructured":"Castro Caldas A, Teodoro T, Ferreira JJ. The launch of opicapone for Parkinson\u2019s disease: negatives versus positives. Expert Opin Drug Saf. 2018;17(3):331\u20137.","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"888_CR100","doi-asserted-by":"publisher","first-page":"733","DOI":"10.3233\/JPD-191593","volume":"9","author":"A Lees","year":"2019","unstructured":"Lees A, Ferreira JJ, Rocha JF, Rascol O, Poewe W, Gama H, et al. Safety profile of opicapone in the management of Parkinson\u2019s disease. J Parkinsons Dis. 2019;9(4):733\u201340.","journal-title":"J Parkinsons Dis"},{"key":"888_CR101","doi-asserted-by":"crossref","unstructured":"Lees ARH, Rocha JF, Magalh\u00e3es D, Soares-da-Silva P. Onset of drug-related adverse events in Parkinson\u2019s disease patients with motor fluctuations treated with opicapone in clinical practice: OPTIPARK post-hoc analysis. Mov Disord. 2020;35.","DOI":"10.1016\/j.parkreldis.2020.06.232"},{"issue":"4","key":"888_CR102","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/S1474-4422(13)70025-5","volume":"12","author":"RA Hauser","year":"2013","unstructured":"Hauser RA, Hsu A, Kell S, Espay AJ, Sethi K, Stacy M, et al. Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson\u2019s disease and motor fluctuations: a phase 3 randomised, double-blind trial. Lancet Neurol. 2013;12(4):346\u201356.","journal-title":"Lancet Neurol"},{"issue":"11","key":"888_CR103","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1002\/mds.21473","volume":"22","author":"G Deuschl","year":"2007","unstructured":"Deuschl G, Vaitkus A, Fox GC, Roscher T, Schremmer D, Gordin A. Efficacy and tolerability of entacapone versus cabergoline in parkinsonian patients suffering from wearing-off. Move Disord. 2007;22(11):1550\u20135.","journal-title":"Move Disord."},{"issue":"12","key":"888_CR104","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/j.parkreldis.2014.08.004","volume":"20","author":"F Stocchi","year":"2014","unstructured":"Stocchi F, Hsu A, Khanna S, Ellenbogen A, Mahler A, Liang G, et al. Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients. Parkinsonism Relat Disord. 2014;20(12):1335\u201340.","journal-title":"Parkinsonism Relat Disord"},{"key":"888_CR105","doi-asserted-by":"crossref","unstructured":"Ferreira JJLA, Poewe P, Rascol O, Santos A, Magalh\u00e3es D, Rocha JF, Soares-da-Silva P. Switching entacapone \u2018non-responders\u2019 to open-label opicapone: change in absolute OFF-time following the 1-year extension BIPARKI study. Move Disord. 2019;34(Suppl. S2):S1\u2013937.","DOI":"10.1016\/j.jns.2019.10.1207"},{"key":"888_CR106","unstructured":"Hauser RALM, Videnovic A, Poewe Q, Rascol O, Ferreira JJ, Liang GS, et al. Effects of once-daily opicapone on duration of overnight OFF and time to morning ON in patients with Parkinson\u2019s disease and motor fluctuations. Ann Neurol. 2020;88(Suppl 25): S189."},{"key":"888_CR107","unstructured":"Videnovic APW, Lees A, Ferreira JJ, Klepitskaya O, Loureiro R, Magalh\u00e3es D, et al. Effect of opicapone and entacapone on early morning-OFF pattern in Parkinson\u2019s disease patients with motor fluctuations. Move Disord. 2020;34(Suppl. S2):S486."},{"issue":"1","key":"888_CR108","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1080\/13696998.2021.1916750","volume":"24","author":"RN Hansen","year":"2021","unstructured":"Hansen RN, Suh K, Serbin M, Yonan C, Sullivan SD. Cost-effectiveness of opicapone and entacapone in reducing OFF-time in Parkinson\u2019s disease patients treated with levodopa\/carbidopa. J Med Econ. 2021;24(1):563\u20139.","journal-title":"J Med Econ"},{"issue":"12","key":"888_CR109","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1007\/s00702-011-0703-9","volume":"118","author":"P Jenner","year":"2011","unstructured":"Jenner P, McCreary AC, Scheller DK. Continuous drug delivery in early- and late-stage Parkinson\u2019s disease as a strategy for avoiding dyskinesia induction and expression. J Neural Transm (Vienna). 2011;118(12):1691\u2013702.","journal-title":"J Neural Transm (Vienna)"},{"issue":"9","key":"888_CR110","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1080\/14737175.2021.1968298","volume":"21","author":"P Jenner","year":"2021","unstructured":"Jenner P, Rocha JF, Ferreira JJ, Rascol O, Soares-da-Silva P. Redefining the strategy for the use of COMT inhibitors in Parkinson\u2019s disease: the role of opicapone. Expert Rev Neurother. 2021;21(9):1019\u201333.","journal-title":"Expert Rev Neurother"},{"issue":"8","key":"888_CR111","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1002\/mds.26731","volume":"31","author":"R Mart\u00ednez-Fern\u00e1ndez","year":"2016","unstructured":"Mart\u00ednez-Fern\u00e1ndez R, Schmitt E, Martinez-Martin P, Krack P. The hidden sister of motor fluctuations in Parkinson\u2019s disease: a review on nonmotor fluctuations. Move Disord. 2016;31(8):1080\u201394.","journal-title":"Move Disord."},{"issue":"Suppl. 1","key":"888_CR112","first-page":"35","volume":"35","author":"GRO Ebersbach","year":"2020","unstructured":"Ebersbach GRO, Ferreira J, Costa R, Rocha JF, Magalh\u00e3es D, Soares-da-Silva P. Efficacy and safety of opicapone in Parkinson\u2019s disease patients according to duration of motor fluctuations: post-hoc analysis of BIPARK-I and II. Move Disord. 2020;35(Suppl. 1):35.","journal-title":"Move Disord."},{"issue":"1","key":"888_CR113","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1468-1331.2012.03866.x","volume":"20","author":"JJ Ferreira","year":"2013","unstructured":"Ferreira JJ, Katzenschlager R, Bloem BR, Bonuccelli U, Burn D, Deuschl G, et al. Summary of the recommendations of the EFNS\/MDS-ES review on therapeutic management of Parkinson\u2019s disease. Eur J Neurol. 2013;20(1):5\u201315.","journal-title":"Eur J Neurol"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-021-00888-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-021-00888-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-021-00888-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T16:31:01Z","timestamp":1666629061000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-021-00888-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,25]]},"references-count":113,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["888"],"URL":"https:\/\/doi.org\/10.1007\/s40263-021-00888-9","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,25]]},"assertion":[{"value":"9 December 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No specific funding was received for this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Margherita Fabbri declares the following conflicts of interest: honoraria to speak: BIAL and AbbVie. Joaquim J. Ferreira declares the following conflicts of interest: consultancy for BIAL and principal investigator of the BIPARK I study; stock ownership in medically related fields: none; consultancies: Ipsen, GlaxoSmithKline, Novartis, Teva, Lundbeck, Solvay, Abbott, Merck-Serono, and Merz; advisory boards: none; partnership: none; honoraria to speak: none; grants: GlaxoSmithKline, Grunenthal, Teva, and Funda\u00e7\u00e3o MSD. Olivier Rascol declares the following conflicts of interest: advisory board and consultancy: BIAL; advisory boards and consultancy: AbbVie, Adamas, Acorda, Addex, AlzProtect, Apopharma, Astrazeneca, Axovant, Biogen, Britannia, Buckwang, Cerespir, Clevexel, Denali, INC Reasearch, Lundbeck, Lupin, Merck, MundiPharma, Neuratris, Neuroderm, Novartis, ONO Pharma, Osmotica, Parexel, Pfizer, Prexton Therapeutics, Quintiles, Roche, Sanofi, Servier, Sunovion, Th\u00e9ranexus, Takeda, Teva, UCB, Vectura, Watermark Research, XenoPort, XO, and Zambon; grant: Agence Nationale de la Recherche (ANR), CHU de Toulouse, France-Parkinson, INSERM-DHOS Recherche Clinique Translationnelle, MJFox Foundation, Programme Hospitalier de Recherche Clinique, European Commission (FP7, H2020), and Cure Parkinson IK; other: grant to participate in a symposium and contribute to the review of an IPMDS article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All co-authors have been substantially involved in the preparation of the manuscript; all the co-authors have also seen and approved the final submitted version and agreed to be accountable for the work. 1. Research project: A. Conception, B. Organization, C. Execution; 2. Statistical Analysis: A. Design, B. Execution, C. Review and Critique; 3. Manuscript Preparation: A. Writing of the first draft, B. Review and Critique. MF: 1A, 1B, 1C, 3A; JJF: 1A, 1B, 3B; OR: 1A, 2A, 3B.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}